Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Psychedelic Drugs LSD

People who ‘microdose’ LSD and magic mushrooms score higher on measures of wisdom, open-mindedness and creativity

by The Conversation
November 4, 2018
in LSD, Microdosing, News
(Photo credit: Jorick Homan)

(Photo credit: Jorick Homan)

Share on TwitterShare on Facebook
Stay informed on the latest psychology and neuroscience research—follow PsyPost on LinkedIn for daily updates and insights.

We just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results.

We compared people who microdose — that is, who take a psychedelic substance such as LSD (lysergic acid diethylamide) or “magic” mushrooms (psilocybin) in very small quantities — with those who don’t, and found that microdosers had healthier scores on key mental health and well-being measures.

Specifically, we found that microdosers scored higher on measures of wisdom, open-mindedness and creativity.

Microdosers also scored lower on measures of dysfunctional attitudes and negative emotionality, which is very promising.

Subtle changes, not hallucinations

Psychedelics microdosing can mean taking five to 20 micrograms of LSD, 0.1 – 0.3 grams of dried psilocybin-containing mushrooms or very low doses of more exotic substances, like 1P-LSD, ALD-52 or 4-AcO-DMT.

No matter the substance, microdosing implies a dose so low that the individual experiences only subtle changes, not hallucinations. People are not “tripping” on a microdose; they just go about their regular day, whether that means studying at school, going to work or taking care of the kids at home.

There has been no published science on whether microdosing works, but despite this, microdosing for self-enhancement and mental health has hit the media.

For example, a 2016 article in Wired magazine described young professionals in San Francisco and Silicon Valley microdosing to enhance their creativity and focus, and to gain a competitive advantage.

Ayelet Waldman attributed her increased well-being to microdosing in A Really Good Day: How Microdosing Made a Mega Difference in My Mood, My Marriage and My Life. More recently, Michael Pollan’s How to Change Your Mind has further attracted mainstream attention to psychedelics.

Higher wisdom and creativity

No experimental study has evaluated psychedelic microdosing, and neither did we.

Randomized placebo-controlled trials are needed to talk definitively about the effects of microdosing. In the meantime, we investigated the experiences of people who already microdose.

Our survey investigated the relationship between microdosing psychedelics and mental health. We recruited participants online, especially from Reddit’s microdosing community.

We asked our study participants about their microdosing patterns by having them fill in some questionnaires. As firm believers in Open Science, we have openly shared all our materials and you can find them here. Our findings are soon to be published in Psychopharmacology and you can access the preprint here.

We found that microdosers scored higher on “wisdom,” but wisdom is a tricky thing to define. In this context, “wisdom” implies considering multiple perspectives, learning from mistakes, being in tune with emotions and people and feeling a sense of connection. Using this definition, microdosers were more “wise.”

They were also more creative and open. If wisdom is tricky, creativity is even more so. In this case, creativity meant finding unusual uses for regular household objects: A brick and a knife. Microdosers came up with more useful, unusual and unique uses for these objects. This is a well-validated measure of divergent thinking, though certainly not the be-all and end-all of creativity.

Microdosers also scored lower on measures of dysfunctional attitudes and negative emotionality. What does that mean?

Well, dysfunctional attitudes and negative emotionality (aka neuroticism are bad. Dysfunctional attitudes are beliefs such as, “my value as a person depends greatly on what others think of me” or “if I ask a question, it makes me look inferior.” Neither of these are true, and they are unhealthy to believe as they imply vulnerability to stress and depression.

Microdosers endorsed less of these unhealthy beliefs. Likewise, high negative emotionality means a higher likelihood of having a mental health disorder, and microdosers had lower negative emotionality.

An exciting future for clinical science

Our results are promising. As promising as they seem, we don’t know whether microdosing actually caused any of these differences.

Maybe people with better mental health were more likely to experiment with microdosing, or perhaps there is some unknown cause that made people both more likely to microdose and to be creative.

At this point, we simply don’t know what caused the differences between the groups — just that these differences existed. We need to run controlled lab studies to actually find out.

Our preliminary work also shows that people report downsides to microdosing. For example, some people found microdosing increased anxiety and mood-instability; increased aches, pains and gastrointestinal distress were also relatively common.

The most common drawback was that microdosing is illegal. Did we forget to mention that? Yes, psychedelics are totally illegal!

LSD and psilocybin were made illegal in the 1971 UN Convention on Psychotropic Substances and remain so today. The exact laws differ depending on where you live, and using analogue substances can sometimes be a legal grey area but, for the most part, microdosing makes you a criminal.

What we need now are controlled lab experiments — randomized placebo-controlled trials of psychedelic microdosing to test safety and efficacy. Microdosing research, alongside full-dose psychedelics, promises an exciting future for clinical science and the study of human flourishing.The Conversation

By Thomas Anderson, PhD student, University of Toronto and Rotem Petranker, PhD student in Clinical Psychology, York University, Canada

This article is republished from The Conversation under a Creative Commons license. Read the original article.

TweetSendScanShareSendPin8ShareShareShareShareShare

RELATED

Microdoses of LSD enhance neural complexity, study finds
Depression

Little-known psychedelic drug shows promise in treating low motivation in depression

May 9, 2025

Researchers investigating the psychedelic drug DOPR discovered that very low doses can enhance motivation in low-performing mice—without triggering behaviors linked to hallucinations. The findings point to the therapeutic potential of psychedelics at doses too low to alter perception.

Read moreDetails
Is childhood trauma linked to challenging ayahuasca experiences? New study has surprising answer
LSD

New study shows LSD changes brain connectivity in unique ways compared to MDMA and amphetamines

March 27, 2025

A new brain imaging study finds LSD alters brain connectivity in unique ways, setting it apart from MDMA and amphetamine despite some shared effects.

Read moreDetails
Study finds microdosing LSD is not effective in reducing ADHD symptoms
ADHD

Study finds microdosing LSD is not effective in reducing ADHD symptoms

March 23, 2025

Microdosing LSD has no clear benefit for ADHD, according to a new placebo-controlled clinical trial published in JAMA Psychiatry.

Read moreDetails
LSD reshapes the brain’s response to pain, neuroimaging study finds
LSD

Psychedelics use is linked to lower odds of frequent bad headaches

March 19, 2025

A study of British adults found that those who had used psychedelics were 25% less likely to report frequent bad headaches, adding to growing research on psychedelics’ potential medical benefits.

Read moreDetails
Relaxation — not mystical experiences — emerges as best predictor of psychedelic therapy’s impact in surprising new study
LSD

Relaxation — not mystical experiences — emerges as best predictor of psychedelic therapy’s impact in surprising new study

November 8, 2024

Recent research found that psychedelic-assisted therapy reduced depressive symptoms, with relaxation during sessions being the strongest predictor of improvement.

Read moreDetails
New research reveals distinct cognitive effects of psychedelics and MDMA
LSD

New research reveals distinct cognitive effects of psychedelics and MDMA

August 22, 2024

Psychedelics impair attention and decision-making during use but may boost creativity afterward. In contrast, MDMA primarily disrupts memory, with no lasting cognitive benefits—highlighting the complex, varied effects of these substances on the brain.

Read moreDetails
LSD reshapes the brain’s response to pain, neuroimaging study finds
LSD

LSD reshapes the brain’s response to pain, neuroimaging study finds

August 20, 2024

LSD alters brain activity and connectivity in key regions associated with pain processing, offering potential insights for pain management and the therapeutic use of psychedelics.

Read moreDetails
LSD microdosing does not appear to improve mood or cognitive ability, according to new placebo-controlled study
Microdosing

Surge in microdosing interest linked to loosened drug regulations, study finds

July 1, 2024

Researchers observed a 1250% increase in microdosing-related Google searches from 2015 to 2023, coinciding with the loosening of cannabis and psychedelic regulations, with over three million searches in 2023 alone.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Neuroscientists discover specific brain cells that enable intelligent behavior

Encountering romantic temptation nudges men and women toward different types of purchases

Biomarkers in spinal fluid may flag frontotemporal dementia before symptoms emerge

Robot-assisted therapy improves communication in autistic children

High caffeine intake linked to greater psychological distress in people with depression

Scientists identify delusion-like cognitive biases that predict conspiracy theory belief

Only a specific dose of psilocybin induces lasting antidepressant-like effects, study suggests

Menopause symptoms may signal future dementia risk, new research suggests

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy